(Stroke. 2000;31:1402.)
© 2000 American Heart Association, Inc.
Original Contributions |
Integrin 
IIbß3 Inhibitor Preserves Microvascular Patency in Experimental Acute Focal Cerebral Ischemia
Presented in part at a meeting of the International Society of Thrombosis and Haemostasis, Washington, DC, August 14–21, 1999.
From the Department of Molecular and Experimental Medicine (T.A., B.R.C., J.A.K., G.J.d.Z.), The Scripps Research Institute, La Jolla, Calif; the Department of Surgery (R.F.), University of Adelaide, The Queen Elizabeth Hospital, Woodville, Australia; and the Integra LifeSciences Corp (C.M., J.F.T., M.P.), Corporate Research Center, San Diego, Calif.
Correspondence to Gregory J. del Zoppo, MD, Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Rd, MEM 132, La Jolla, CA 92037. E-mail grgdlzop{at}hermes.scripps.edu
Background and
Purpose—Platelets become activated and accumulate in
brain microvessels of the ischemic microvascular bed after
experimental focal cerebral ischemia. The binding of
glycoprotein IIb/IIIa (integrin
IIbß3) on platelets to fibrinogen is
the terminal step in platelet adhesion and aggregation. This study
tests the hypothesis that inhibition of platelet-fibrin(ogen)
interactions may prevent microvascular occlusion after experimental
middle cerebral artery occlusion (MCA:O).
Methods—TP9201 is a novel Arg-Gly-Asp (RGD)-containing integrin
IIbß3 inhibitor. Microvascular
patency after 3-hour MCA:O and 1-hour reperfusion within the
ischemic and nonischemic basal ganglia was compared in
adolescent male baboons who received high-dose TP9201 (group A:
IC80 in heparin, n=4), low-dose TP9201 (group B:
IC30 in heparin, n=4), or no treatment (group C: n=4)
before MCA:O.
Results—After MCA:O, microvascular patency decreased
significantly in group C. However, in the ischemic zones of
groups A and B compared with group C, patencies were significantly
greater in the 4.0- to 7.5-µm-diameter (capillary) and 7.5- to
30.0-µm-diameter vessels (2P<0.05). A dose-dependent
increase in hemorrhagic transformation was seen in group A (3 of 4
animals) compared with group B (1 of 4 animals), and no
hemorrhage was visible in group C (
2
analysis for trend, P<0.05).
Conclusions—Platelet activation contributes significantly to
ischemic microvascular occlusion. Occlusion formation may be
prevented by this RGD–integrin IIbß3
inhibitor at a dose that does not produce clinically
significant parenchymal hemorrhage. The effect of microvascular
patency on neuron recovery can now be tested.
Editorial Comment
Presented in part at a meeting of the International Society of Thrombosis and Haemostasis, Washington, DC, August 14–21, 1999.
Department of Anesthesiology/Critical Care Medicine Johns Hopkins Medical Institutions Baltimore, Maryland
This article has been cited by other articles:
 |
|
 |
|
  G. J. del Zoppo and R. Milner Integrin-Matrix Interactions in the Cerebral Microvasculature Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 1966 - 1975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Mathew, H. M. Rinder, B. R. Smith, M. F. Newman, and C. S. Rinder Transcerebral Platelet Activation After Aortic Cross-Clamp Release is Linked to Neurocognitive Decline. Ann. Thorac. Surg., May 1, 2006; 81(5): 1644 - 1649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mangiafico, M. Cellerini, P. Nencini, G. Gensini, and D. Inzitari Intravenous Glycoprotein IIb/IIIa Inhibitor (Tirofiban) followed by Intra-Arterial Urokinase and Mechanical Thrombolysis in Stroke AJNR Am. J. Neuroradiol., November 1, 2005; 26(10): 2595 - 2601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Littleton-Kearney, J. M. Gaines, K. P. Callahan, S. J. Murphy, and P. D. Hurn Effects of Estrogen on Platelet Reactivity After Transient Forebrain Ischemia in Rats Biol Res Nurs, October 1, 2005; 7(2): 135 - 145. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Mangiafico, M. Cellerini, P. Nencini, G. Gensini, and D. Inzitari Intravenous Tirofiban With Intra-Arterial Urokinase and Mechanical Thrombolysis in Stroke: Preliminary Experience in 11 Cases Stroke, October 1, 2005; 36(10): 2154 - 2158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hsiao, K. H. Lin, Y. Chang, T. L. Chen, N. H. Tzu, D. S. Chou, and J. R. Sheu Protective Mechanisms of Inosine in Platelet Activation and Cerebral Ischemic Damage Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1998 - 2004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Hussain, A. Shuaib, and Z. A. Siddiqi Spinal cord transient ischemic attacks: A possible role for abciximab Neurology, February 22, 2005; 64(4): 761 - 762. [Full Text] [PDF]
|
|
|
|
 |
|
 B.-Q. Zhao, Y. Ikeda, H. Ihara, T. Urano, W. Fan, S. Mikawa, Y. Suzuki, K. Kondo, K. Sato, N. Nagai, et al. Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice Blood, April 1, 2004; 103(7): 2610 - 2616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Moriguchi, T. Aoki, K. Mihara, N. Tojo, N. Matsuoka, and S. Mutoh Antithrombotic Effects of FK419, a Novel Nonpeptide Platelet GPIIb/IIIa Antagonist, in a Guinea Pig Photochemically Induced Middle Cerebral Artery Thrombosis Model: Comparison with Ozagrel and Argatroban J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1094 - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Seitz, M. Hamzavi, U. Junghans, P. A. Ringleb, C. Schranz, and M. Siebler Thrombolysis With Recombinant Tissue Plasminogen Activator and Tirofiban in Stroke: Preliminary Observations Stroke, August 1, 2003; 34(8): 1932 - 1935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Junghans and M. Siebler Cerebral Microembolism Is Blocked by Tirofiban, a Selective Nonpeptide Platelet Glycoprotein IIb/IIIa Receptor Antagonist Circulation, June 3, 2003; 107(21): 2717 - 2721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Belayev, L. Khoutorova, T. A. Deisher, A. Belayev, R. Busto, Y. Zhang, W. Zhao, and M. D. Ginsberg Neuroprotective Effect of SolCD39, a Novel Platelet Aggregation Inhibitor, on Transient Middle Cerebral Artery Occlusion in Rats Stroke, March 1, 2003; 34(3): 758 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Eckert, C. Koch, G. Thomalla, J. Roether, and H. Zeumer Acute Basilar Artery Occlusion Treated With Combined Intravenous Abciximab and Intra-arterial Tissue Plasminogen Activator: Report of 3 Cases Stroke, May 1, 2002; 33(5): 1424 - 1427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Junghans, R. J. Seitz, A. Ritzl, H.-J. Wittsack, G. R. Fink, H.-J. Freund, and M. Siebler Ischemic brain tissue salvaged from infarction by the GP IIb/IIIa platelet antagonist tirofiban Neurology, February 12, 2002; 58(3): 474 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Watson, R. Prado, A. Veloso, J-P. Brunschwig, and W. D. Dietrich Cerebral Blood Flow Restoration and Reperfusion Injury After Ultraviolet Laser-Facilitated Middle Cerebral Artery Recanalization in Rat Thrombotic Stroke Stroke, February 1, 2002; 33(2): 428 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Lapchak, D. M. Araujo, D. Song, and J. A. Zivin The Nonpeptide Glycoprotein IIb/IIIa Platelet Receptor Antagonist SM-20302 Reduces Tissue Plasminogen Activator-Induced Intracerebral Hemorrhage After Thromboembolic Stroke Stroke, January 1, 2002; 33(1): 147 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Y. Lee, J. H. Heo, S. I. Lee, and P. H. Yoon Rescue treatment with abciximab in acute ischemic stroke Neurology, June 12, 2001; 56(11): 1585 - 1587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. del Zoppo, K. J. Becker, and J. M. Hallenbeck Inflammation After Stroke: Is It Harmful? Arch Neurol, April 1, 2001; 58(4): 669 - 672. [Full Text] [PDF]
|
|